W-135 and Y tetanus toxoid conjugate vaccine C tetravalent meningococcal serogroups A

could be used in vaccination programs irrespective of the pre-vaccination status with polysaccharide vaccine.

Also Known As:

tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine; MenACWY-TT

Networked: 17 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Bacterial Vaccines: 529
      - Meningococcal Vaccines: 375
        W-135 and Y tetanus toxoid conjugate vaccine C tetravalent meningococcal serogroups A: 17

Experts

1.	Baine, Yaela: 5 articles (01/2018 - 03/2011)
2.	Van der Wielen, Marie: 5 articles (01/2018 - 03/2013)
3.	Miller, Jacqueline M: 4 articles (10/2015 - 03/2011)
4.	Bianco, Veronique: 4 articles (02/2015 - 03/2011)
5.	Balmer, Paul: 2 articles (01/2020 - 01/2018)
6.	Serra, Lidia: 2 articles (01/2020 - 01/2020)
7.	Webber, Chris: 2 articles (01/2020 - 01/2018)
8.	Fischbach, Thomas: 2 articles (01/2018 - 05/2013)
9.	Jastorff, Archana: 2 articles (01/2018 - 01/2018)
10.	Kolhe, Devayani: 2 articles (01/2018 - 10/2015)

Related Diseases

1.	Meningococcal Infections 05/01/2013 - "When administered to European school-age children, MenACWY-TT has a clinically acceptable safety profile and, when compared with MenC-CRM₁₉₇, the potential to broaden protection against meningococcal disease caused by serogroups A, W-135 and Y while maintaining protection against MenC. " 01/01/2020 - "Additionally, these findings indicate that in subjects who receive primary MenACWY-TT vaccination as toddlers, the antibody response to booster MenACWY-TT vaccination lasts for up to 6 years and suggest that immune memory is afforded at least into early adolescence, which is an age group at increased risk of invasive meningococcal disease." 10/06/2015 - "No SAEs related to vaccination or cases of meningococcal disease were reported up to Year 5. These results suggest that a single dose of MenACWY-TT could protect at least 72 % of vaccinated adolescents and adults against meningococcal disease at least 5 years post-vaccination. " 03/05/2013 - "These results suggest that MenACWY-TT could protect adolescents and adults against meningococcal disease up to three years post-vaccination. " 01/01/2022 - "This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent meningococcal disease from serogroups A, C, W, Y. "
2.	Tetanus 11/22/2022 - "Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine." 01/01/2018 - "This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults. " 01/01/2018 - "We assessed co-administration of quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT), human papillomavirus 16/18 AS04-adjuvanted vaccine (AS04-HPV16/18) and tetanus-diphtheria-acellular pertussis vaccine (Tdap) in girls and young women. " 01/01/2018 - "This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. "
3.	Diphtheria 01/01/2018 - "We assessed co-administration of quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT), human papillomavirus 16/18 AS04-adjuvanted vaccine (AS04-HPV16/18) and tetanus-diphtheria-acellular pertussis vaccine (Tdap) in girls and young women. " 01/01/2020 - "Available meningococcal vaccines targeting serogroups A, C, W, and Y (MenACWY) include those conjugated to diphtheria toxoid (MenACWY-D), diphtheria protein cross-reactive material 197 (MenACWY-CRM197), and tetanus toxoid (MenACWY-TT). " 01/01/2018 - "This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. "
4.	Whooping Cough (Pertussis) 01/01/2018 - "Co-administration of MenACWY-TT, AS04-HPV16/18 and Tdap was non-inferior to MenACWY-TT administered alone or to Tdap co-administered with AS04-HPV16/18 in terms of immunogenicity for all vaccine components, except pertussis antigens. " 01/01/2018 - "This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. "
5.	Hepatitis B 01/01/2018 - "This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers. "

Related Drugs and Biologics

1.	Conjugate Vaccines
2.	Vaccines
3.	Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
4.	Toxoids
5.	Pentetic Acid (DTPA)
6.	Carrier Proteins (Binding Protein)
7.	10-valent pneumococcal conjugate vaccine
8.	twinrix
9.	Tetanus Toxoid (Vaccine, Tetanus)
10.	Meningococcal Vaccines (Meningococcal Vaccine)

Related Therapies and Procedures

1.	Stem Cell Transplantation